Despite the widening choice of oral and injectable anti-hyperglycaemic agents to treat T2D and the availability of long and fast-acting insulin analogs, many people struggle to achieve recommended glycaemic targets and are at risk of developing long-term micro- and macro-vascular complications2. Here, INS is linked to type 2 diabetes mellitus.